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Loss of immune checkpoint (IC) Programmed Death-1 (PD-1) and PD-Ligand1 (PD-L1)
expression has been implicated in the immunopathology of Giant Cell Arteritis (GCA). The
contribution of the negative immune checkpoint V-domain Immunoglobulin-containing
suppressor of T cell activation (VISTA) to GCA pathology has not yet been studied. The
aim of our study was to investigate if expression of VISTA and other IC molecules by
peripheral blood (PB) immune cells is modulated in GCA and at the site of vascular
inflammation. In addition, we assessed the effect of VISTA-Ig engagement on in vitro
CD4+ T helper (Th) lineage differentiation. To this end, frequencies of monocytes
expressing CD80/86, PD-L1, PD-L2, and VISTA were determined in blood samples
from 30 GCA patients and 18 matched healthy controls by flow cytometry. In parallel,
frequencies of CD4+ cells expressing CD28, Cytotoxic T-Lymphocyte-associated
antigen-4 (CTLA-4), PD-1, and VISTA were determined. Immunohistochemistry was
employed to detect VISTA, PD-1, and PD-L1-expressing cells in temporal artery biopsies
(TABs) diagnostic of GCA. Furthermore, the effect of VISTA-Ig on in vitro CD4+ Th
lineage differentiation in patients and controls was determined. Our study shows that
frequencies of CD80/CD86+ and VISTA+ monocytes were decreased in treated GCA
patients only. Moreover, proportions of PD-1+ and VISTA+ Th cells were significantly
decreased in GCA patients. Clear infiltration of VISTA+, PD1+, and PD-L1+ cells was
seen in GCA TABs. Finally, VISTA-Ig engagement failed to suppress Th1, Th17, and Tfh
lineage development in GCA. Our results indicate that decreased expression of VISTA
may facilitate development of pathogenic Th1 and Th17 cells in GCA.
Keywords: immune checkpoints, V-domain immunoglobulin-containing suppressor of T cell activation (VISTA),
programmed death-1 (PD-1), vasculitis, giant cell arteritis
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INTRODUCTION
The immune system regulates the immune response by balancing
a complex network of cell surface molecules required to defend
the body against threats whilst maintaining tolerance to self-
antigens. T cell activation is of paramount importance to face
novel antigenic challenges. The activation of T cells requires two
signals to reach full activation: the first signal occurs through
the T cell receptor (TCR), which recognizes a cognate peptide
antigen when bound to the major histocompatibility complex
(MHC) molecules on the surface of antigen presenting cells
(APCs). The second signal is provided by immune checkpoint
(IC) molecules also known as co-stimulatory and co-inhibitory
molecules which determine cell activation or anergy. The
magnitude of the response will be proportional to the sum
of molecular pathways that strengthen or weaken the immune
responses (1). Thus, failure of immune checkpoint regulation
may lead to the development of T cell-mediated autoimmune
diseases such as Giant Cell Arteritis (GCA).
GCA is the most frequent form of primary vasculitis in the
elderly population. Both age-related restructuring of the immune
system together with the remodeling processes of the vascular
wall facilitate the development of the disease (2). Defective
immune responses in age-related immune disorders such as GCA
are not fully understood, nevertheless, considerable progress has
been made over the last decades identifying CD4+ T cells and
monocytes/macrophages as pivotal players in the pathogenic
process of GCA (3–7). Briefly, the immunopathological model of
GCA occurs as follows: in vasculitic lesions, vascular dendritic
cells (vasDCs) are easily activated due to reduced expression of
PD-L1 (8). Signals mediated via activated vasDCs are responsible
for the recruitment of T cells into the vessel wall. Once recruited,
T cells are locally activated by the same vasDCs and are
polarized toward Th1 and Th17 development by Th1- (IL-12)
and Th17- (IL-1b, IL6, IL23) driving cytokine cues. Th1 and Th17
cells produce large amounts of IFN-È and IL-17, respectively,
which favor a state of chronic inflammation and the subsequent
recruitment of CD8+ T cells and monocytes into the vessel
wall. These monocytes differentiate into macrophages amplifying
vascular inflammation, damage, and ultimately triggering the
vascular remodeling processes (3, 4, 6, 7, 9).
Thus, both the Th1 and Th17 axes are important contributors
to disease activity and inflammation inGCA (10–13). In addition,
IL-21-producing CD4+ T cells have been reported to correlate
with disease activity and to contribute to Th1 and Th17
expansion in GCA (14). The relationship between IC expression
modulation and the different Th lineages has been studied both in
GCA and in cancer. In cancerous environments, PD-1 blockade
augmented Th1 and Th17 responses (15). In a humanized model
of vasculitis, PD-1 blockade enhanced vascular inflammation
and tissue production of T cell cytokines IFN-È and IL-17 (8).
In contrast, little is known about V-domain Immunoglobulin-
containing suppressor of T cell activation (VISTA), an inhibitory
receptor expressed on myeloid cells and T cells that has been
reported to behave as both ligand and receptor to suppress
T cell activation (16, 17). Interestingly, Wang et. al. recently
proposed that V-Set and Immunoglobulin domain containing
TABLE 1 | Clinical and Laboratory characteristics of GCA patients
(Cross-sectional study).
Sex (F/M) 18/12
Age [years, median (range)] 73 (56–85)
ESR [mm/h, median (range)] 26 (4–104)
CRP [mg/l, median (range)] 5.5 (0.3–134)
Active/remission 13/17
Receiving GC/not receiving GC 15/15
Methotrexate 4
Diagnostic method 10/14/6
Biopsy/PET/combination (biopsy + PET)
Clinical manifestations at time of diagnosis
cranial/systemic/combination
9/5/14
Concomitant polymyalgia rheumatica (PMR) 6
Disease duration [months, median (range)] 18 (0–60)
Claudication 15
Visual ischemia 6
3 (VSIG-3) could also act as a ligand for VISTA delivering
a negative signal thereby, inhibiting T cell activation (18).
However, information on the role of VISTA in shaping CD4+ T
cell differentiation is limited. In healthy donors, VISTA enhanced
the conversion of human naïve T cells into FoxP3+ T cells
(16), yet, such information is currently lacking in the context of
GCA development.
Changes in checkpoint molecule expression have been
linked to the development of a chronic pro-inflammatory state
facilitating the development of (auto) inflammatory disorders
in the elderly (19–21). Particularly in GCA pathogenesis,
abnormalities in the PD-1/PD-L1 pathway have been reported
(8, 22). Moreover, immune checkpoint inhibitor (ICI) therapy
in cancer was found to trigger GCA development (21, 23–25).
In an effort to understand the possible added contribution of
IC pathways to the dysregulation of CD4+ T cells in GCA, we
aimed to 1: investigate the expression of different IC molecules
on CD4+ T cells of GCA patients and compare it with age-
and sex-matched healthy controls (HCs), 2: assess checkpoint
expression at the vascular site in GCA and non-GCA biopsies and




In a cross-sectional study, fresh blood samples were obtained
from 30 GCA patients. Fifteen patients were receiving
glucocorticoids (GC), i.e., prednisolone. Four of these patients
were also receiving methotrexate. The remaining 15 patients
were not receiving GC or methotrexate at the time of blood-
withdrawal (Table 1). Blood samples were obtained before
noon and all donors were non-fasted/took their prednisolone
in the morning. GCA diagnosis was either confirmed by a
positive temporal artery biopsies (TABs) and/or positive 18F-
fluorodeoxyglucose-positron emission tomography-computed
tomography (FDG-PET/CT) (Supplementary Table S1A). As
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controls, we obtained fresh blood samples from 18 sex- and
age-matched healthy controls (HCs) who were screened for
past or actual morbidities and pharmacological treatments
(Supplementary Table S1B).
At time of diagnosis, patients were examined for both cranial
and/or systemic symptoms. For cranial symptoms, patients had
to present one of the following: new headache, temporal artery
abnormality, scalp tenderness, jaw/tongue claudication, vision
loss (ischemic symptom), amaurosis fugax (ischemic symptom),
transient ischemic attack (TIA), or cerebrovascular accident
(CVA). The following systemic symptoms reflecting GCA disease
activity were taken into account: arm/leg claudication or PMR
clinic, and/or two of the following symptoms: fever, weight loss,
malaise or night sweats. Symptoms were scored only if they could
not be explained by other causes (i.e., infection).
Written informed consent was obtained from all study
participants. All procedures were in compliance with the
declaration of Helsinki. The study was approved by the
institutional review board of the UMCG (METc 2012/375 for HC
and METc 2010/222 for GCA patients).
Treatment of the Patients
GCA patients were initially treated with 40–60 mg/day of
prednisone. Tapering of prednisone treatment started after 2–4
weeks, based on normalization of clinical signs and symptoms
accompanied by normalization of the erythrocyte sedimentation
rate (ESR) and/or C-reactive protein (CRP). After 3 months, the
median prednisone dose was 15mg/day. Seventeen GCA patients
were in remission after 3 months of GC treatment. Remission
was defined based on the absence of clinical signs and symptoms
and normal ESR (<30 mm/h) and/or C-reactive protein (CRP)
<5 mg/L.
Staining for Surface Markers
(Flow Cytometry)
Fresh blood samples were collected in EDTA anticoagulant tubes
and processed within 2 h. The samples were stained in two
separate multi-color flow cytometry panels. The first panel (Panel
1) included the following monoclonal antibodies: anti-CD3, anti-
CD4, anti-CD45RA, anti-CD25, anti-CD28, anti-CTLA-4, anti-
CD279 (PD-1), and anti-VISTA (Supplementary Table S2A).
The second multi-color flow cytometry panel (Panel 2) included
the following monoclonal antibodies: anti-CD3, anti-CD16,
anti-CD14, anti-CD274 (PD-L1), anti-CD273 (PD-L2), anti-
CD80, anti-CD86, and anti-VISTA (Supplementary Table S2B).
After this, cells were fixed and erythrocytes were lysed using
FACS Lysing solution (BD Biosciences, Durham, NC, USA)
according to instructions of the manufacturer. Immediately
thereafter, samples were measured on a BD LSR-II flow
cytometer. Data were collected for at least 1 × 105 cells and
analyzed with Kaluza Analysis Software (Beckman Coulter).
Proportions of marker positive/negative cell populations were
calculated by quadrant dot-plot analysis based on proper isotype
controls. In panel 1, CD4+ T cell subsets were identified
and gated as previously described (Figure 4A) (26). For gating
strategy see (Supplementary Figure S1A). In panel 2, classical
(CD14brightCD16neg), intermediate (CD14brightCD16+), and
non-classical (CD14dimCD16+) monocytes subsets were gated
as previously described (Supplementary Figure S1B) (27). In
parallel, the absolute numbers of CD3, CD4, and CD8 T-cells
and monocytes were determined according to the MultiTest
TruCount method (BD), as described by the manufacturer. Data
were acquired on a FACSCanto-II (BDBiosciences) and analyzed
with FACS Canto Clinical Software (BD).
Effect of VISTA-Ig Engagement on CD4+ T
Cell Differentiation
Ninety-six-well flat-bottom plates were coated with purified anti-
CD3 (clone OKT3,) at 2.5µg/mL mixed together with 10 µg/ ml
VISTA-Ig (R&D Systems) or control-Ig protein (110-HG, R&D
Systems) in PBS for 2 h at 37◦C and stored at 4◦C overnight.
Wells were washed twice with RPMI 1640 before adding cells.
Peripheral blood mononuclear cells (PBMC) were isolated from
heparinized blood with Lymphoprep (Axis-Shield). Immediately
after, CD4+ T cells were isolated by negative selection using the
MagniSortTM Human CD4+ T cell Enrichment Kit (Thermo
Fisher Scientific, Waltham, MA., USA) according to instructions
of the manufacturer. CD4+T cells were plated at 1 × 105 cells
per well in RPMI1640 with 10% heat-inactivated fetal bovine
serum and gentamycin. Next, soluble anti-CD28 (clone L293,
BD Biosciences) at 250 ng/mL was added to the culture media.
After 5 days in culture at 37◦C, cells were stained with zombie
NIR fixable viability kit (Biolegend) according to instructions of
the manufacturer and surface marker CD4. Next, cells were fixed
and permeabilized with FoxP3 staining buffer set (eBiosciences)
followed by intracellular staining for transcription factors: FoxP3,
T-bet, RORgt, BCL6, GATA3 (Supplementary Table S2C).
Immunohistochemistry (IHC)
Temporal artery biopsies (TABs) were obtained from 5 GCA
patients before start of GC treatment. The tissue was fixed in
formalin and paraffin embedded. Sections were deparaffinized
in xylene and rehydrated in graded ethanol. After antigen
retrieval in 1mM EDTA (pH 8) and endogenous peroxidase
blocking, sections were incubated with a rabbit monoclonal anti-
VISTA antibody (Clone: D1L2G; Dilution: 1:200; Cell Signaling,
Danvers, USA) or an isotype control antibody. The primary
antibody was visualized using an EnVision+ Kit (HRP Rabbit
AEC+, Dako K4009) and sections were counterstained with
hematoxylin. Stainings for PD-1 (Clone: MRQ-22; Dilution:
ready to use (R.T.U); Ventana) and PD-L1 (Clone: SP263;
Dilution: R.T.U; Ventana) were performed in a Benchmark
Ultra automated immunostainer (Ventana, Tucson, Arizona)
using pre-diluted antibodies and following the manufacturer’s
protocols (Supplementary Table S2D). Non-GCA TABs (n =
5) and human tonsil tissue were used as controls (Temporal
arteries were considered negative for GCA if there were no typical
histological findings). Stained sections were scanned using a
Nanozoomer Digital Pathology Scanner (NDP Scan U10074–01,
Hamamatsu Photonics K.K., Hamamatsu, Japan).
Detection of VISTA, PD-1 and PD-L1-expressing cells
(irrespective of intensity) in affected temporal artery biopsy
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FIGURE 1 | Frequencies of immune checkpoint molecule expressing circulating monocytes of GCA patients and HCs. Frequencies of peripheral monocytes
expressing CD80/86 and VISTA (plotted on left y-axis) were decreased in GCA patients (n = 30) compared with HCs (n = 18). Frequencies of peripheral monocytes
expressing PD-1 ligands (PD-L1 and PD-L2) (plotted on right y-axis) were comparable between GCA patients and HCs. The red horizontal lines represent the median.
Significant differences by the Mann-Whitney U-test are indicated: *P < 0.05, **P < 0.01, ns, non-significant.
FIGURE 2 | Effect of GC treatment on CD80/CD86 and VISTA-expressing monocytes. (A) Decreased proportions of CD80/CD86+ circulating monocytes of treated
GCA patients, no differences between untreated GCA patients and HC. (B) Decreased proportions of VISTA+ circulating monocytes of treated GCA patients, no
differences between untreated GCA patients and HC (HC: n = 18, GCA treated: n = 15, and GCA untreated: n = 15). The red horizontal lines represent the median.
Significant differences by the Mann-Whitney U-test are indicated: *P < 0.05, ***P < 0.001, ns, non-significant.
areas was semi-quantitatively scored on a five-point scale (0–
4): 0 = no positive cells, 1 = occasional positive cells (0–1%
estimated positive), 2 = low numbers of positive cells (>1–
20%), 3 = moderate numbers of positive cells (>20–50%), 4 =
high numbers of positive cells (more than 50%). Affected regions
containing infiltrating cells were scored. Scoring was performed
by two independent investigators, trained by a pathologist and
average scores were calculated.
Double staining was performed in limited number of
samples to confirm the co-localization of VISTA with T cells
using CD3 or with macrophages using pu.1 (29). MultiVision
Polymer Detection system (MultiVision anti-rabbit/AP + anti-
mouse/HRP polymers; Thermo Fisher Scientific, Fremont, USA)
was used according to the manufacturer’s instructions. Binding
of primary antibodies was visualized with the chromogens of the
MultiVision kit, LVBlue, and LVRed.
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FIGURE 3 | Frequencies of immune checkpoint molecule expressing circulating CD4+ Th cells in GCA patients and HCs. Frequencies of CD28+ (plotted on left
y-axis) and CTLA-4+ (plotted on right y-axis) peripheral CD4+ T cells were comparable between GCA patients (n = 30) and HCs (n = 18). Proportions of PD-1+ and
VISTA+ (plotted on right y-axis) peripheral CD4+ T cells were decreased in patients compared with HCs. The red horizontal lines represent the median. Significant
differences by the Mann-Whitney U-test are indicated: **P < 0.01, ns, non-significant.
Statistical Analysis
Non-parametric tests were used for data analysis. The Mann-
Whitney U-test was used to compare data of patients with HC.
Paired samples were analyzed with theWilcoxon signed rank test.
Analyses were performed with GraphPad Prism 7.0 software. P-
values of<0.05 (2-tailed) were considered statistically significant.
RESULTS
Reduced Frequencies of Negative IC
Molecule Expressing Monocytes in
Peripheral Blood of GCA Patients
Is Treatment-Related
We first assessed the numbers of monocytes in peripheral
blood (PB) of GCA patients and HCs. Total monocyte counts
were comparable between groups. Next, we analyzed the
expression of CD80/86, as ligands of CD28 and Cytotoxic T-
Lymphocyte-associated antigen-4 (CTLA-4) and the expression
of PD-L1/PD-L2 as ligands for PD-1 on the surface of
monocytes. As VISTA has been reported to behave both as
ligand and receptor to suppress T cell activation (30, 31),
we measured VISTA+ cells in both panels (panel 1 and
2, Supplementary Tables S2A,S2B). The frequencies of PD-
L1 and PD-L2-expressing cells were not different between
GCA patients and HCs. Interestingly, the proportions of
circulating monocytes expressing CD80/CD86 and VISTA were
decreased in GCA patients (Figure 1). As GC treatment has
a major effect on immune cells, especially monocytes (27,
32), we analyzed expression in GCA patients who were not
receiving GC (n = 15) and GCA patients receiving GC
(n = 15) separately. Indeed, the proportional decrease of
monocytes expressing CD80/CD86 and VISTA was treatment
related (Figure 2).
Reduced Frequencies of Negative IC
Molecule Expressing CD4+ T Cells in
Peripheral Blood of GCA Patients
Similarly, we measured the absolute numbers and frequencies of
CD4+ T cells. No significant differences between GCA patients
and HCs were observed (Supplementary Figure S2). Next, we
analyzed the frequencies of expression of IC expressing-CD4+
T cells. Proportions of co-stimulatory molecule CD28+ and
its outcompeting co-inhibitory molecule CTLA-4+ cells were
similar between patients and HCs. We sought to confirm that
frequencies of circulating PD-1+ Th cells were reduced in
GCA patients (8). Indeed, proportions of these cells in GCA
patients were lower than in HCs. In addition, proportions
of VISTA+ Th cells were also decreased in GCA patients
(Figure 3). Contrary to the outcome seen on IC expression on
monocytes, no effect of GC treatment on IC expression by
CD4+ T cells was detected. Decreased expression of the negative
IC was seen in both patients receiving GCs and not receiving
GCs (Supplementary Figure 3).
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FIGURE 4 | Immune checkpoint expression in CD45RA and CD25 defined CD4+ T cell subsets. (A) Flow cytometric gating strategy for analysis of CD45RA and
CD25 defined subsets in peripheral blood, as reported by Miyara et al. (28) and adapted by van der Geest (26). Naïve and memory CD4+ T cells subsetted into seven
cell fractions. Memory fractions: Memory CD25- (fraction 5), Memory CD25dim (fraction 4), Memory CD25int (fraction 3), and Memory CD25high Treg (fraction 2). Naïve
fractions: Naïve CD25- (fraction 6), CD45RA+ CD25dim (fraction 7), and Naïve CD25int Treg (fraction 1). A representative flow cytometry plot is shown for a GCA
patient. Frequencies of CD28+ cells (B), CTLA-4+ cells (C), PD-1+ cells (D), and VISTA+ cells (E) within memory and naïve fractions of GCA patients (n = 30) and
HCs (n = 18). The red horizontal lines represent the median. Significant differences by the Mann-Whitney U-test are indicated: *P < 0.05, **P < 0.01, ns,
non-significant.
Immune Checkpoint Expression in CD45RA
and CD25 Defined CD4+ T Cell Subsets
Next, we determined the frequencies of IC molecule-expressing
cells within functionally distinct populations of naïve and
memory CD4+ Th cells by CD45RA and CD25 expression
(Figure 4A) according to Miyara et al. (28) and adapted by
van der Geest et al. to add one age-associated subset (26). The
memory fractions include Memory CD25- (fraction 5), Memory
CD25dim (fraction 4),Memory CD25int (fraction 3), andMemory
CD25high Treg (fraction 2). Within fractions 5 and 4, frequencies
of CD28+, PD-1+, and VISTA+ cells were decreased in GCA
patients compared to HCs. Memory CD25int (fraction 3) which
has intermediate expression of CD25 but is considered as a non-
regulatory T cell subset, showed a decrease in the proportions of
PD-1+ and VISTA+ cells of GCA patients compared to HCs.
Interestingly, within fraction 2, the activated Treg subset, we
found unchanged frequencies of cells expressing the negative
IC molecules measured, but a decrease in proportions of cells
expressing the positive co-stimulator CD28 in GCA patients
compared to HCs, thereby suggesting a potentially decreased
Treg activity (Figure 4). Within the naïve fractions we identified
Naïve CD25- (fraction 6), Naïve CD25int Treg (fraction 1)
from the Miyara classification plus the age-associated subset
CD45RA+ CD25dim (fraction 7) cells which have been shown to
represent a broad and functional reservoir of naïve T cells in the
elderly population (26). Within these naïve fractions, frequencies
of VISTA+ cells were decreased in GCA patients compared to
HCs. Proportions of PD-1–expressing cells were also significantly
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FIGURE 5 | Increase in VISTA+, PD-1+, and PD-L1+ cells in temporal artery biopsies of GCA patients. (A) Immunohistochemical staining for VISTA, PD-1, and
PD-L1 in non-GCA temporal artery biopsies (TABs) and (B) in representative TABs diagnostic of GCA. (C–E) Semi-quantitative mean scores of VISTA+, PD-1+, and
PD-L1+ cells in inflammatory areas of GCA TABs (n = 5) and non-GCA TABs (n = 5). Scores are given for the adventitia (Adv), media (Med, infiltrating cells only), and
intima (Int). Data are presented as scatter plots. The horizontal red lines represent the median.
decreased in conventional naïve T cell fractions 6 and 7 but
not in naïve CD25int Treg (fraction 1). Frequencies of CTLA-
4-expressing cells within the memory and naïve fractions were
comparable between GCA patients and HC (Figure 4C).
Increased Numbers of VISTA+, PD-1+, and
PD-L1+ Cells in Infiltrates of GCA TAB
As we found PD-1 and VISTA to be modulated in Th cells
from GCA patients, we next assessed expression of these
checkpoints, including the ligand PD-L1, at lesional sites using
immunohistochemistry on GCA diagnostic TABs (Figure 5
and Supplementary Figure S4 for isotype control staining).
We found VISTA-expressing cells to be increased within the
infiltrates of the adventitia, media and intima layer of the
vessel wall when compared to non-GCA biopsies (Figure 5C).
PD-1-expressing cells were found mostly within the infiltrates
of the medial layer of the vessel wall (Figure 5D). Finally,
PD-L1-expressing cells were also increased in GCA biopsies
compared with non-GCA TABs (Figure 5E). In addition, double
staining for VISTA/CD3 and VISTA/pu.1 confirmed that T cells
as well as macrophages in the vascular wall express VISTA
(Supplementary Figure S5).
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FIGURE 6 | CD4+ T cell differentiation upon VISTA engagement. CD4+ T cells were negatively isolated from PBMCs. Cells were cultured in 96-well flat-bottom plates
and stimulated for 5 days at 37◦C in anti-CD3 (2.5 ug/mL) coated plates simultaneously coated with either control Ig or VISTA-Ig (both 10 ug/mL). Soluble anti-CD28
was added at 250 ng/mL. After 5 days, CD4+ T cell differentiation was assessed by measuring the expression of intracellular transcription factors (T-bet, RORÈt,
BCL6, GATA3, and FoxP3). (A) Frequency of transcription factor expression of CD4+ T cells from healthy controls when engaged to control Ig (light blue) and
VISTA-Ig (dark blue) (n = 6). (B) Frequency of transcription factor expression of CD4+ T cells from GCA patients when engaged to control Ig (light orange) and
VISTA-Ig (dark orange) (n = 6). (C) Radar plot of the frequency of transcription factor expression of CD4+ T cell from HC (blue) and GCA patients (orange) combined.
Individual values represent the median. Significant differences by Wilcoxon signed-rank test are indicated: *P < 0.05, ns, non-significant.
CD4+ T Cells of GCA Patients Are
Unresponsive to VISTA-Ig Engagement
To evaluate whether the decrease in the frequencies of VISTA+
cells seen in GCA patients would translate into a functional
effect, we performed experiments using recombinant human
VISTA on human T cells. To this end, VISTA-Ig or control
Ig was immobilized on plates with anti-CD3 (OKT3) and
soluble anti-CD28 was added to provide appropriate co-
stimulatory signaling. Unstimulated samples served as controls.
Dead cells were excluded from the analysis and gates were set
according to unstimulated samples (Supplementary Figure S6).
The ability of CD4+ T cells to differentiate into Th subsets
(Th1, Th17, Tfh, Th2, and Treg) was assessed by measuring the
expression of intracellular transcription factors (T-bet, RORÈt,
BCL6, GATA3, and FoxP3) (Supplementary Figure S7). The
effect of VISTA-Ig engagement on CD4+ T cell differentiation
in HCs showed a decrease of T-bet, RORÈt and BCL6-
expressing cells when compared to Ig control engagement
(Supplementary Figures S8, S9) The expression of GATA3 and
FoxP3 remained unchanged. On the other hand, applying the
same differentiation conditions to CD4+ T cells of GCA patients,
we found that VISTA-Ig engagement failed to modulate any of
these transcription factors, hence facilitating Th1, Th17, and Tfh
lineage differentiation (Figure 6).
DISCUSSION
We found that expression of IC molecules PD-1 and VISTA
is reduced in both memory and naïve CD4+ T cells of GCA
patients. Our functional studies show that VISTA plays a role
in skewing CD4+ lineage differentiation and that VISTA-Ig
engagement failed to suppress Th1, Th17, and Tfh lineage
development in GCA. Reduced VISTA expressionmay thus favor
the expansion of pathogenic Th1 and Th17 responses in GCA
patients. Our VISTA data strengthen the hypothesis of failing
immune regulation in GCA development.
The molecular mechanism by which VISTA exerts its
inhibitory effects is not yet fully understood. However, there
have been several reports of VISTA’s dual behavior, as a ligand
and receptor, suppressing T cell activation (33–36). We here
provide evidence for a role of VISTA in shaping Th lineage
differentiation. Previously, VISTA was shown to enhance the
conversion of human naïve T cells into FoxP3+ T cells of
healthy individuals (16). In our in vitro model we did not
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detect a role for VISTA-Ig in the enhancement of FoxP3+ T
cells. However, we show that in GCA, VISTA engagement failed
to suppress Th1, Th17, and Tfh differentiation, consequently,
reduced VISTA expression may favor the development of
pathogenic Th1 and Th17 responses in GCA. Although the
contribution of Th1 and Th17 to GCA is clearly established,
the contribution of Tfh cells seems counterintuitive as GCA is
not characterized by disease-specific autoantibodies. Yet, the IL-
21 producing capacity of Tfh cells could contribute to IL-21-
mediated expansion of pathogenic Th1 and Th17 in GCA (14).
Clearly, the mechanism by which VISTA mediates these effects
and the role of IL-21 producing Tfh cells in GCA remain to
be established.
The modulation of IC on monocytes was found to be related
to GC treatment. GC represent an important therapeutic strategy
to treat various inflammatory and autoimmune diseases such as
GCA. GC are immunomodulatory agents which regulate gene
expression and signaling pathways by binding to intracellular
receptors (37, 38). In addition, some of the effects of GC
exposure include decreased DC ability to present antigens and
mount an optimal T cell response. This is a consequence of GC
preventing the upregulation of MHC class II and costimulatory
molecules CD80 and CD86 (37, 38). Hence, it is likely that
GC modulated these IC on monocytes of GCA patients in
our study.
Here, we report lower frequencies of circulating PD-1 and
VISTA-expressing CD4+ T cells in GCA patients. This was
independent of treatment, suggesting that the IC modulation
was likely due to vasculitis-associated inflammation. Our data
confirms the previously reported decrease of circulating PD-1+
CD4+ T cells in GCA patients (8). Here, we extend these findings
by showing reduced frequencies of VISTA+ Th cells in GCA
patients. Moreover, we found reduced frequencies of CD28, PD-
1, and VISTA-expressing cells in most memory T cell subsets.
Interestingly, memory Tregs showed a decreased proportion of
CD28+ cells which could translate into a diminished regulatory
activity. Remarkably, we found that frequencies of PD-1 and
VISTA-expressing cells were already reduced in all naïve T cell
fractions. The latter finding suggests that naïve T cells in GCA
may already be imprinted by systemic inflammatory processes
although no direct correlation was found between IC decreased
expression on immune cells and inflammatory markers (i.e.,
CRP, ESR). Decreased immunoinhibitory checkpoint expression
is thought to be related to persistence of T cell activation.
The combination of low CD28 activated Tregs together with
decreased negative IC in both memory and naïve T cells
might facilitate the activation of effector/autoreactive T cells
in GCA. In our in vitro study, favoring the stimulation and
differentiation of naïve T cells, we found VISTA-Ig engagement
to downmodulate T-bet, RORÈt and BCL6 lineage differentiation
in CD4+ T cells of HCs. In contrast, CD4+ T cells of
GCA patients were found to be non-responsive to VISTA-
Ig engagement.
We also investigated IC expression in GCA lesional sites.
Our data showed, consistent with increased infiltration of the
vessel wall in GCA TABs, higher numbers of VISTA+ cells
throughout all three layers of the vessel wall. We found higher
numbers of PD-1-expressing cells in granulomatous lesions of
GCA patients, particularly in the media layer when compared
to non-GCA control tissues. Lastly, within the vessel wall of
GCA patients, we found higher numbers of PD-L1+ cells. The
increase of negative IC within the vessel wall could indicate
a futile attempt to decrease immune activation and prevent
further damage.
Persistent activation of T cells, especially Th1 and Th17
cells, is a well-known phenomenon occurring in GCA patients
(3, 4, 9, 11). Furthermore, our in vitro T cell differentiation
studies substantiate the notion of persistent activation as
VISTA-Ig mediated suppression did not suppress CD4+
lineage differentiation in GCA patients. This could mean that
VISTA expression on the surface of these cells is insufficient
to properly transmit the negative signal. This may also
be true at the site of inflammation. Despite the increase
of VISTA-expressing cells in the infiltrated layers of the
vascular wall, vascular inflammation and occlusion appears
to be an ongoing process. Future validation studies should
be performed in an independent larger cohort to confirm
our observations.
Growing evidence indicates that the impaired PD-1/PD-L1
axis plays an important role not only in cancer but also in
GCA and a variety of autoimmune diseases (39–41). Here, we
demonstrate that the VISTA signaling pathway fails to control
Th1, Th17, and Tfh lineage differentiation in GCA. The data
add to a further understanding of unchecked pathogenic T
cell responses in GCA and may aid the development of new
therapeutic strategies.
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